Ana B. Oton

2.2k total citations
39 papers, 1.7k citations indexed

About

Ana B. Oton is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ana B. Oton has authored 39 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Ana B. Oton's work include Lung Cancer Treatments and Mutations (19 papers), Soft tissue tumor case studies (7 papers) and Lung Cancer Research Studies (7 papers). Ana B. Oton is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Soft tissue tumor case studies (7 papers) and Lung Cancer Research Studies (7 papers). Ana B. Oton collaborates with scholars based in United States, Germany and Italy. Ana B. Oton's co-authors include Chandra P. Belani, William E. Gooding, Suresh S. Ramalingam, Taofeek K. Owonikoko, Camille Ragin, Emanuela Taioli, Robert C. Doebele, D. Ross Camidge, Paul A. Bunn and Wilbur A. Franklin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Ana B. Oton

38 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ana B. Oton United States	18	1.1k	1.0k	418	237	127	39	1.7k
Barbara Melosky Canada	28	1.1k 1.0×	1.3k 1.2×	388 0.9×	334 1.4×	241 1.9×	116	2.0k
Amelia Insa Spain	18	697 0.6×	1.1k 1.1×	317 0.8×	277 1.2×	97 0.8×	63	1.5k
Katherine Liau United States	19	843 0.8×	1.1k 1.1×	861 2.1×	441 1.9×	185 1.5×	36	2.0k
Juergen Wolf Germany	22	914 0.8×	1.0k 1.0×	630 1.5×	282 1.2×	334 2.6×	92	1.8k
Sofia Paul United States	11	1.9k 1.7×	1.8k 1.8×	464 1.1×	244 1.0×	120 0.9×	24	2.7k
Andrew W. Hahn United States	21	712 0.7×	498 0.5×	375 0.9×	346 1.5×	81 0.6×	103	1.3k
Francisco Sapunar United Kingdom	14	846 0.8×	1.1k 1.0×	414 1.0×	522 2.2×	102 0.8×	33	1.7k
Josiane Otto France	20	906 0.8×	1.1k 1.1×	228 0.5×	259 1.1×	156 1.2×	59	1.6k
Jerome H. Goldschmidt United States	16	1.0k 1.0×	1.3k 1.3×	356 0.9×	160 0.7×	221 1.7×	68	1.9k
Albert Font Spain	22	874 0.8×	720 0.7×	498 1.2×	381 1.6×	216 1.7×	75	1.7k

Countries citing papers authored by Ana B. Oton

Since Specialization

Citations

This map shows the geographic impact of Ana B. Oton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana B. Oton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana B. Oton more than expected).

Fields of papers citing papers by Ana B. Oton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana B. Oton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana B. Oton. The network helps show where Ana B. Oton may publish in the future.

Co-authorship network of co-authors of Ana B. Oton

This figure shows the co-authorship network connecting the top 25 collaborators of Ana B. Oton. A scholar is included among the top collaborators of Ana B. Oton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana B. Oton. Ana B. Oton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ratan, Ravin, Bernd Kasper, Thierry Alcindor, et al.. (2025). Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial. Journal of Clinical Oncology. 43(34). 3646–3651.

Graaf, Winette T.A. van der, Nam Bui, Gina Z. D’Amato, et al.. (2025). 67MO Long-term nirogacestat treatment in adult patients with desmoid tumors: Updated efficacy and safety from the phase III DeFi trial. ESMO Open. 10. 104381–104381. 1 indexed citations

Vincenzi, Bruno, Nam Bui, Palma Dileo, et al.. (2024). Efficacy of nirogacestat in participants with poor prognostic factors for desmoid tumors: Analyses from the randomized phase 3 DeFi study.. Journal of Clinical Oncology. 42(16_suppl). 11556–11556. 1 indexed citations

Loggers, Elizabeth T., Rashmi Chugh, Noah Federman, et al.. (2024). Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study. Cancer. 130(16). 2812–2821. 6 indexed citations

Loggers, Elizabeth T., Rashmi Chugh, Lee Hartner, et al.. (2024). Monitoring ovarian function in oncology studies: Results and insights from the DeFi phase 3 study of nirogacestat in desmoid tumor.. Journal of Clinical Oncology. 42(16_suppl). 11520–11520. 1 indexed citations

Bektas, Meryem, et al.. (2023). Desmoid Tumors: A Comprehensive Review. Advances in Therapy. 40(9). 3697–3722. 29 indexed citations

Fernandez, M., et al.. (2023). Disease and economic burden of surgery in desmoid tumors: a review. Expert Review of Pharmacoeconomics & Outcomes Research. 23(6). 607–618. 5 indexed citations

Garon, Edward B., Giorgio V. Scagliotti, Oliver Gautschi, et al.. (2020). Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. ESMO Open. 5(1). e000567–e000567. 8 indexed citations

Hess, Lisa M., et al.. (2020). Treatment sequencing for the care of patients with advanced or metastatic non-small cell lung cancer in the United States. Current Medical Research and Opinion. 37(3). 469–476. 3 indexed citations

10.

Langer, Corey J., Antoinette J. Wozniak, Cesare Gridelli, et al.. (2017). Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies. Clinical Lung Cancer. 18(5). 489–496. 13 indexed citations

11.

Hess, Lisa M., David M. Kern, Gebra Cuyún Carter, et al.. (2017). Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer (RESOUNDS) in the United States: Study Protocol. JMIR Research Protocols. 6(10). e195–e195. 4 indexed citations

12.

Hess, Lisa M., et al.. (2016). PS01.72: Payer and Patient Out-of-Pocket Costs: A Projection of the Financial Burden of Non–Small Cell Lung Cancer Care in the United States Through 2040. Journal of Thoracic Oncology. 11(11). S315–S316. 1 indexed citations

13.

Rolfo, Christian, Christian Caglevic, Denisse Bretel, et al.. (2016). Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015. ESMO Open. 1(4). e000055–e000055. 22 indexed citations

14.

Weickhardt, Andrew, Robert C. Doebele, Ana B. Oton, et al.. (2012). A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 7(2). 419–426. 46 indexed citations

15.

Doebele, Robert C., Xian Lu, Christopher Sumey, et al.. (2012). Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer. Cancer. 118(18). 4502–4511. 223 indexed citations

16.

Weickhardt, Andrew, Micol S. Rothman, Katja Kiseljak‐Vassiliades, et al.. (2012). Rapid‐onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 118(21). 5302–5309. 69 indexed citations

17.

Camidge, D. Ross, Scott A. Kono, Xian Lu, et al.. (2011). Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed. Journal of Thoracic Oncology. 6(4). 774–780. 195 indexed citations

18.

Oton, Ana B., Hong Wang, Xavier Leleu, et al.. (2008). Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leukemia & lymphoma. 49(9). 1738–1744. 32 indexed citations

19.

Feng, Rentian, et al.. (2007). The histone deacetylase inhibitor, PXD101, potentiates bortezomib‐induced anti‐multiple myeloma effect by induction of oxidative stress and DNA damage. British Journal of Haematology. 139(3). 385–397. 98 indexed citations

20.

Feng, Rentian, Ana B. Oton, Kenneth D. Patrene, et al.. (2006). Combination of the Proteasome Inhibitor Bortezomib and a Histone Deacetylase Inhibitor PXD101 Results in Synergistic Inhibition of Osteoclastogenesis and Significantly Stronger Inhibition of Multiple Myeloma Growth In Vitro and In Vivo.. Blood. 108(11). 507–507. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact